Targeting lymphatic vessel functions through tyrosine kinases

Journal of Angiogenesis Research

Volumn 2, Issue 1, 2010, Pages

  Williams, Steven P ^a,b,c   Karnezis, Tara ^a,c   Achen, Marc G ^a,c   Stacker, Steven A ^a,c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CETUXIMAB; EPHRIN RECEPTOR B4; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMATINIB; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TIE 1 RECEPTOR; TRASTUZUMAB; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; CELL JUNCTION; CELL MIGRATION; CHRONIC MYELOID LEUKEMIA; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHEDEMA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; STEM CELL;

EID: 77956051343     PISSN: None     EISSN: 20402384     Source Type: Journal    
DOI: 10.1186/2040-2384-2-13     Document Type: Review

References (139)

1. Lymphangiogenesis: Molecular mechanisms and future promise. T Tammela K Alitalo, Cell 2010 140 460 476 10.1016/j.cell.2010.01.045 20178740
2. Tumor angiogenesis: therapeutic implications. J Folkman, N Engl J Med 1971 285 1182 1186 10.1056/NEJM197108122850711 4938153
3. Lymphangiogenesis and cancer metastasis. SA Stacker MG Achen L Jussila ME Baldwin K Alitalo, Nat Rev Cancer 2002 2 573 583 10.1038/nrc863 12154350
4. VEGF receptor signalling - in control of vascular function. AK Olsson A Dimberg J Kreuger L Claesson-Welsh, Nat Rev Mol Cell Biol 2006 7 359 371 10.1038/nrm1911 16633338
5. Molecular regulation of angiogenesis and lymphangiogenesis. RH Adams K Alitalo, Nat Rev Mol Cell Biol 2007 8 464 478 10.1038/nrm2183 17522591
6. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. E Kriehuber S Breiteneder-Geleff M Groeger A Soleiman SF Schoppmann G Stingl D Kerjaschki D Maurer, J Exp Med 2001 194 797 808 10.1084/jem.194.6.797 11560995
7. Molecular characterization of lymphatic endothelial cells. S Podgrabinska P Braun P Velasco B Kloos MS Pepper M Skobe, Proc Natl Acad Sci USA 2002 99 16069 16074 10.1073/pnas.242401399 12446836
8. Lymphatic vessels in cancer metastasis: bridging the gaps. R Shayan MG Achen SA Stacker, Carcinogenesis 2006 27 1729 1738 10.1093/carcin/bgl031 16597644
9. Functionally specialized junctions between endothelial cells of lymphatic vessels. P Baluk J Fuxe H Hashizume T Romano E Lashnits S Butz D Vestweber M Corada C Molendini E Dejana DM McDonald, J Exp Med 2007 204 2349 2362 10.1084/jem.20062596 17846148
10. On the origin of the lymphatic system from the veins and the development of the lymph hearts and thoracic duct in the pig. F Sabin, American Journal of Anatomy 1902 1 367 389 10.1002/aja.1000010310
11. On the development of the superficial lymphatics in the skin of the pig. F Sabin, American Journal of Anatomy 1904 3 183 195 10.1002/aja.1000030205
12. Lymphatic vasculature development. G Oliver, Nat Rev Immunol 2004 4 35 45 10.1038/nri1258 14704766
13. The angiogenic switch in carcinogenesis. V Baeriswyl G Christofori, Semin Cancer Biol 2009 19 329 337 10.1016/j.semcancer.2009.05.003 19482086
14. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. GN Naumov LA Akslen J Folkman, Cell Cycle 2006 5 1779 1787 16931911
15. Clinical patterns of metastasis. SP Leong B Cady DM Jablons J Garcia-Aguilar D Reintgen J Jakub S Pendas L Duhaime R Cassell M Gardner,, et al. Cancer Metastasis Rev 2006 25 221 232 10.1007/s10555-006-8502-8 16770534
16. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. SJ Mandriota L Jussila M Jeltsch A Compagni D Baetens R Prevo S Banerji J Huarte R Montesano DG Jackson,, et al. EMBO J 2001 20 672 682 10.1093/emboj/20.4.672 11179212
17. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. M Skobe T Hawighorst DG Jackson R Prevo L Janes P Velasco L Riccardi K Alitalo K Claffey M Detmar, Nat Med 2001 7 192 198 10.1038/84643 11175850
18. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. SA Stacker C Caesar ME Baldwin GE Thornton RA Williams R Prevo DG Jackson S Nishikawa H Kubo MG Achen, Nat Med 2001 7 186 191 10.1038/84635 11175849
19. Lymphangiogenesis and lymphatic metastasis in breast cancer. S Ran L Volk K Hall MJ Flister, Pathophysiology 2009 20036110
20. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. T Tammela A Saaristo T Holopainen J Lyytikka A Kotronen M Pitkonen U Abo-Ramadan S Yla-Herttuala TV Petrova K Alitalo, Nat Med 2007 13 1458 1466 10.1038/nm1689 18059280
21. Treatment of lymphangioma in children: our experience of 128 cases. T Okazaki S Iwatani T Yanai H Kobayashi Y Kato T Marusasa GJ Lane A Yamataka, J Pediatr Surg 2007 42 386 389 10.1016/j.jpedsurg.2006.10.012 17270554
22. The protein tyrosine kinase family of the human genome. DR Robinson YM Wu SF Lin, Oncogene 2000 19 5548 5557 10.1038/sj.onc.1203957 11114734
23. The protein kinase complement of the human genome. G Manning DB Whyte R Martinez T Hunter S Sudarsanam, Science 2002 298 1912 1934 10.1126/science. 1075762 12471243
24. A renaissance for SRC. TJ Yeatman, Nat Rev Cancer 2004 4 470 480 10.1038/nrc1366 15170449
25. Src kinases as therapeutic targets for cancer. LC Kim L Song EB Haura, Nat Rev Clin Oncol 2009 6 587 595 10.1038/nrclinonc.2009.129 19787002
26. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. SP Sardi J Murtie S Koirala BA Patten G Corfas, Cell 2006 127 185 197 10.1016/j.cell.2006.07.037 17018285
27. Targeting the cancer kinome through polypharmacology. ZA Knight H Lin KM Shokat, Nat Rev Cancer 2010 10 130 137 10.1038/nrc2787 20094047
28. Targeting tumor stroma. MG Achen SA Stacker, Curr Cancer Drug Targets 2008 8 446 10.2174/156800908785699397 18781890
29. VEGF-mediated signal transduction in lymphatic endothelial cells. F Bahram L Claesson-Welsh, Pathophysiology 2009 20006475
30. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. BI Terman M Dougher-Vermazen ME Carrion D Dimitrov DC Armellino D Gospodarowicz P Bohlen, Biochem Biophys Res Commun 1992 187 1579 1586 10.1016/0006-291X(92)90483-2 1417831
31. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. C de Vries JA Escobedo H Ueno K Houck N Ferrara LT Williams, Science 1992 255 989 991 10.1126/science.1312256 1312256
32. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). MG Achen M Jeltsch E Kukk T Makinen A Vitali AF Wilks K Alitalo SA Stacker, Proc Natl Acad Sci USA 1998 95 548 553 10.1073/pnas.95.2.548 9435229
33. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. V Joukov K Pajusola A Kaipainen D Chilov I Lahtinen E Kukk O Saksela N Kalkkinen K Alitalo, Embo J 1996 15 290 298 8617204
34. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. T Makinen T Veikkola S Mustjoki T Karpanen B Catimel EC Nice L Wise A Mercer H Kowalski D Kerjaschki,, et al. EMBO J 2001 20 4762 4773 10.1093/emboj/20.17.4762 11532940
35. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. SJ Mandriota L Jussila M Jeltsch A Compagni D Baetens R Prevo S Banerji J Huarte R Montesano DG Jackson,, et al. EMBO J 2001 20 672 682 10.1093/emboj/20.4.672 11179212
36. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. P Haiko T Makinen S Keskitalo J Taipale MJ Karkkainen ME Baldwin SA Stacker MG Achen K Alitalo, Mol Cell Biol 2008 28 4843 4850 10.1128/MCB.02214-07 18519586
37. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Dixelius T Makinen M Wirzenius MJ Karkkainen C Wernstedt K Alitalo L Claesson-Welsh, J Biol Chem 2003 278 40973 40979 10.1074/jbc.M304499200 12881528
38. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. I Nilsson F Bahram X Li L Gualandi S Koch M Jarvius O Soderberg A Anisimov I Kholova B Pytowski,, et al. EMBO J 2010 29 1377 1388 10.1038/emboj.2010.30 20224550
39. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). GB Whitaker BJ Limberg JS Rosenbaum, J Biol Chem 2001 276 25520 25531 10.1074/jbc.M102315200 11333271
40. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. Y Xu L Yuan J Mak L Pardanaud M Caunt I Kasman B Larrivee R Del Toro S Suchting A Medvinsky,, et al. J Cell Biol 2010 188 115 130 10.1083/jcb.200903137 20065093
41. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. B Favier A Alam P Barron J Bonnin P Laboudie P Fons M Mandron JP Herault G Neufeld P Savi,, et al. Blood 2006 108 1243 1250 10.1182/blood-2005-11-4447 16621967
42. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. T Karpanen CA Heckman S Keskitalo M Jeltsch H Ollila G Neufeld L Tamagnone K Alitalo, FASEB J 2006 20 1462 1472 10.1096/fj.05-5646com 16816121
43. Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. L Wang SK Dutta T Kojima X Xu R Khosravi-Far SC Ekker D Mukhopadhyay, PLoS One 2007 2 1161 10.1371/journal.pone.0001161 18000534
44. Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. MG Achen SA Stacker, Int J Cancer 2006 119 1755 1760 10.1002/ijc.21899 16557570
45. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. R Cao MA Bjorndahl MI Gallego S Chen P Religa AJ Hansen Y Cao, Blood 2006 107 3531 3536 10.1182/blood-2005-06-2538 16424394
46. Hepatocyte growth factor promotes lymphatic vessel formation and function. K Kajiya S Hirakawa B Ma I Drinnenberg M Detmar, EMBO J 2005 24 2885 2895 10.1038/sj.emboj.7600763 16052207
47. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. JW Shin M Min F Larrieu-Lahargue X Canron R Kunstfeld L Nguyen JE Henderson A Bikfalvi M Detmar YK Hong, Mol Biol Cell 2006 17 576 584 10.1091/mbc.E05-04-0368 16291864
48. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. M Bjorndahl R Cao LJ Nissen S Clasper LA Johnson Y Xue Z Zhou D Jackson AJ Hansen Y Cao, Proc Natl Acad Sci USA 2005 102 15593 15598 10.1073/pnas.0507865102 16230630
49. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. G Thurston, Cell Tissue Res 2003 314 61 68 10.1007/s00441-003-0749-6 12915980
50. Differential response of lymphatic, venous and arterial endothelial cells to angiopoietin-1 and angiopoietin-2. VP Nguyen SH Chen J Trinh H Kim BL Coomber DJ Dumont, BMC Cell Biol 2007 8 10 10.1186/1471-2121-8-10 17341311
51. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. DJ Dumont G Gradwohl GH Fong MC Puri M Gertsenstein A Auerbach ML Breitman, Genes Dev 1994 8 1897 1909 10.1101/gad.8.16.1897 7958865
52. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. TN Sato Y Tozawa U Deutsch K Wolburg-Buchholz Y Fujiwara M Gendron-Maguire T Gridley H Wolburg W Risau Y Qin, Nature 1995 376 70 74 10.1038/376070a0 7596437
53. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. C Suri PF Jones S Patan S Bartunkova PC Maisonpierre S Davis TN Sato GD Yancopoulos, Cell 1996 87 1171 1180 10.1016/S0092-8674(00) 81813-9 8980224
54. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. MC Puri J Rossant K Alitalo A Bernstein J Partanen, EMBO J 1995 14 5884 5891 8846781
55. Loss of endothelial Tie1 receptor impairs lymphatic vessel development-brief report. G D'Amico EA Korhonen M Waltari P Saharinen P Laakkonen K Alitalo, Arterioscler Thromb Vasc Biol 2010 30 207 209 10.1161/ATVBAHA.109.196618 19910638
56. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. F Shalaby J Rossant TP Yamaguchi M Gertsenstein XF Wu ML Breitman AC Schuh, Nature 1995 376 62 66 10.1038/376062a0 7596435
57. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. NW Gale G Thurston SF Hackett R Renard Q Wang J McClain C Martin C Witte MH Witte D Jackson,, et al. Dev Cell 2002 3 411 423 10.1016/S1534-5807(02)00217-4 12361603
58. Regulation of angiogenesis by Eph-ephrin interactions. S Kuijper CJ Turner RH Adams, Trends Cardiovasc Med 2007 17 145 151 10.1016/j.tcm.2007.03.003 17574121
59. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. EB Pasquale, Nat Rev Cancer 2010 10 165 180 10.1038/nrc2806 20179713
60. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. T Makinen RH Adams J Bailey Q Lu A Ziemiecki K Alitalo R Klein GA Wilkinson, Genes Dev 2005 19 397 410 10.1101/gad.330105 15687262
61. Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis. YH Kim H Hu S Guevara-Gallardo MT Lam SY Fong RA Wang, Development 2008 135 3755 3764 10.1242/dev.022475 18952909
62. Prox1 induces lymphatic endothelial differentiation via integrin alpha9 and other signaling cascades. K Mishima T Watabe A Saito Y Yoshimatsu N Imaizumi S Masui M Hirashima T Morisada Y Oike M Araie,, et al. Mol Biol Cell 2007 18 1421 1429 10.1091/mbc.E06-09-0780 17287396
63. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. MM Goldenberg, Clin Ther 1999 21 309 318 10.1016/S0149-2918(00)88288-0 10211534
64. Trastuzumab - mechanism of action and use in clinical practice. CA Hudis, N Engl J Med 2007 357 39 51 10.1056/NEJMra043186 17611206
65. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. LG Presta H Chen SJ O'Connor V Chisholm YG Meng L Krummen M Winkler N Ferrara, Cancer Res 1997 57 4593 4599 9377574
66. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian SM Steinberg HX Chen SA Rosenberg, N Engl J Med 2003 349 427 434 10.1056/NEJMoa021491 12890841
67. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. NI Goldstein M Prewett K Zuklys P Rockwell J Mendelsohn, Clin Cancer Res 1995 1 1311 1318 9815926
68. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. RS Herbst WK Hong, Semin Oncol 2002 29 18 30 12422310
69. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. G Bergers S Song N Meyer-Morse E Bergsland D Hanahan, J Clin Invest 2003 111 1287 1295 12727920
70. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. JK Smith NM Mamoon RJ Duhe, Oncol Res 2004 14 175 225 14977353
71. An overview of small-molecule inhibitors of VEGFR signaling. SP Ivy JY Wick BM Kaufman, Nat Rev Clin Oncol 2009 6 569 579 10.1038/nrclinonc.2009.130 19736552
72. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. A Hermans N Heisterkamp M von Linden S van Baal D Meijer D van der Plas LM Wiedemann J Groffen D Bootsma G Grosveld, Cell 1987 51 33 40 10.1016/0092-8674(87)90007-9 2820585
73. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. JB Konopka SM Watanabe ON Witte, Cell 1984 37 1035 1042 10.1016/0092-8674(84)90438-0 6204766
74. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. E Buchdunger J Zimmermann H Mett T Meyer M Muller BJ Druker NB Lydon, Cancer Res 1996 56 100 104 8548747
75. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. BJ Druker S Tamura E Buchdunger S Ohno GM Segal S Fanning J Zimmermann NB Lydon, Nat Med 1996 2 561 566 10.1038/nm0596-561 8616716
76. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. T Schindler W Bornmann P Pellicena WT Miller B Clarkson J Kuriyan, Science 2000 289 1938 1942 10.1126/science.289.5486.1938 10988075
77. Rational design of inhibitors that bind to inactive kinase conformations. Y Liu NS Gray, Nat Chem Biol 2006 2 358 364 10.1038/nchembio799 16783341
78. VEGF-targeted therapy: mechanisms of anti-tumour activity. LM Ellis DJ Hicklin, Nat Rev Cancer 2008 8 579 591 10.1038/nrc2403 18596824
79. Drug insight: VEGF as a therapeutic target for breast cancer. BP Schneider GW Sledge Jr, Nat Clin Pract Oncol 2007 4 181 189 10.1038/ncponc0740 17327858
80. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. J Konner J Dupont, Clin Colorectal Cancer 2004 4 Suppl 2 81 85 10.3816/CCC.2004.s.013 15479484
81. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. AC Lockhart ML Rothenberg J Dupont W Cooper P Chevalier L Sternas G Buzenet E Koehler JA Sosman LH Schwartz,, et al. J Clin Oncol 2010 28 207 214 10.1200/JCO.2009.22.9237 19949018
82. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Y Wu Z Zhong J Huber R Bassi B Finnerty E Corcoran H Li E Navarro P Balderes X Jimenez,, et al. Clin Cancer Res 2006 12 6573 6584 10.1158/1078-0432.CCR-06-0831 17085673
83. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. JY Hsu HA Wakelee, BioDrugs 2009 23 289 304 10.2165/11317600-000000000-00000 19754219
84. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Y Krupitskaya HA Wakelee, Curr Opin Investig Drugs 2009 10 597 605 19513949
85. TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. J Mackey K Gelmon M Martin N McCarthy T Pinter M Rupin H Youssoufian, Clin Breast Cancer 2009 9 258 261 10.3816/CBC.2009.n.044 19933083
86. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. JL Spratlin RB Cohen M Eadens L Gore DR Camidge S Diab S Leong C O'Bryant LQ Chow NJ Serkova,, et al. J Clin Oncol 2010 28 780 787 10.1200/JCO.2009.23.7537 20048182
87. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. K Persaud JC Tille M Liu Z Zhu X Jimenez DS Pereira HQ Miao LA Brennan L Witte MS Pepper B Pytowski, J Cell Sci 2004 117 2745 2756 10.1242/jcs.01138 15150322
88. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. B Pytowski J Goldman K Persaud Y Wu L Witte DJ Hicklin M Skobe KC Boardman MA Swartz, J Natl Cancer Inst 2005 97 14 21 10.1093/jnci/dji003 15632376
89. From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway. M Cardo-Vila RJ Giordano RL Sidman LF Bronk Z Fan J Mendelsohn W Arap R Pasqualini, Proc Natl Acad Sci USA 2010 107 5118 5123 10.1073/pnas.0915146107 20190183
90. From combinatorial peptide selection to drug prototype (I): Targeting the vascular endothelial growth factor receptor pathway. RJ Giordano M Cardo-Vila A Salameh CD Anobom BD Zeitlin DH Hawke AP Valente FC Almeida JE Nor RL Sidman,, et al. Proc Natl Acad Sci USA 2010 107 5112 5117 10.1073/pnas.0915141107 20190181
91. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. D Strumberg JW Clark A Awada MJ Moore H Richly A Hendlisz HW Hirte JP Eder HJ Lenz B Schwartz, Oncologist 2007 12 426 437 10.1634/theoncologist. 12-4-426 17470685
92. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. D Strumberg H Richly RA Hilger N Schleucher S Korfee M Tewes M Faghih E Brendel D Voliotis CG Haase,, et al. J Clin Oncol 2005 23 965 972 10.1200/JCO.2005.06.124 15613696
93. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. DB Mendel AD Laird X Xin SG Louie JG Christensen G Li RE Schreck TJ Abrams TJ Ngai LB Lee,, et al. ClinCancer Res 2003 9 327 337
94. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. RJ Motzer MD Michaelson BG Redman GR Hudes G Wilding RA Figlin MS Ginsberg ST Kim CM Baum SE DePrimo,, et al. J Clin Oncol 2006 24 16 24 10.1200/JCO.2005.02.2574 16330672
95. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. S Faivre C Delbaldo K Vera C Robert S Lozahic N Lassau C Bello S Deprimo N Brega G Massimini,, et al. J Clin Oncol 2006 24 25 35 10.1200/JCO.2005.02.2194 16314617
96. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. R Kumar VB Knick SK Rudolph JH Johnson RM Crosby MC Crouthamel TM Hopper CG Miller LE Harrington JA Onori,, et al. Mol Cancer Ther 2007 6 2012 2021 10.1158/1535-7163.MCT-07-0193 17620431
97. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRb/B-RAF. EA Murphy DJ Shields K Stoletov E Dneprovskaia M McElroy JI Greenberg J Lindquist LM Acevedo S Anand BK Majeti,, et al. Proc Natl Acad Sci USA 2010 107 4299 4304 10.1073/pnas. 0909299107 20154271
98. Inhibition of the T790 M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. SB Gendreau R Ventura P Keast AD Laird FM Yakes W Zhang F Bentzien B Cancilla J Lutman F Chu,, et al. Clin Cancer Res 2007 13 3713 3723 10.1158/1078-0432.CCR-06-2590 17575237
99. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. NA Pennell TJ Lynch Jr, Oncologist 2009 14 399 411 10.1634/theoncologist.2008-0276 19357226
100. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. N Cheng DM Brantley H Liu Q Lin M Enriquez N Gale G Yancopoulos DP Cerretti TO Daniel J Chen, Mol Cancer Res 2002 1 2 11 10.1186/1476-4598-1-2 12496364
101. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. JM Summy JG Trevino DP Lesslie CH Baker WC Shakespeare Y Wang R Sundaramoorthi CA Metcalf JA Keats TK Sawyer GE Gallick, Mol Cancer Ther 2005 4 1900 1911 10.1158/1535-7163.MCT-05-0171 16373705
102. A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. N Ali M Yoshizumi Y Fujita Y Izawa Y Kanematsu K Ishizawa K Tsuchiya S Yano S Sone T Tamaki, J Pharmacol Sci 2005 98 130 141 10.1254/jphs.FP0040850 15937404
103. Src tyrosine kinase inhibition suppresses lymphangiogenesis in vitro and in vivo. I Ischenko H Seeliger P Camaj A Kleespies M Guba ME Eichhorn KW Jauch CJ Bruns, Curr Cancer Drug Targets 2010 10 546 553 10.2174/156800910791517181 20370688
104. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. I Ischenko M Guba M Yezhelyev A Papyan G Schmid T Green M Fennell KW Jauch CJ Bruns, Angiogenesis 2007 10 167 182 10.1007/s10456-007- 9071-3 17486419
105. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. T Tammela G Zarkada E Wallgard A Murtomaki S Suchting M Wirzenius M Waltari M Hellstrom T Schomber R Peltonen,, et al. Nature 2008 454 656 660 10.1038/nature07083 18594512
106. Blocking neuropilin-2 function inhibits tumor cell metastasis. M Caunt J Mak WC Liang S Stawicki Q Pan RK Tong J Kowalski C Ho HB Reslan J Ross,, et al. Cancer Cell 2008 13 331 342 10.1016/j.ccr.2008.01.029 18394556
107. The art and design of genetic screens: RNA interference. M Boutros J Ahringer, Nat Rev Genet 2008 9 554 566 10.1038/nrg2364 18521077
108. Systematic genome-wide screens of gene function. AE Carpenter DM Sabatini, Nat Rev Genet 2004 5 11 22 10.1038/nrg1248 14708012
109. High-throughput RNAi screening in cultured cells: a user's guide. CJ Echeverri N Perrimon, Nat Rev Genet 2006 7 373 384 10.1038/nrg1836 16607398
110. Genome-wide functional analysis of human cell-cycle regulators. M Mukherji R Bell L Supekova Y Wang AP Orth S Batalov L Miraglia D Huesken J Lange C Martin,, et al. Proc Natl Acad Sci USA 2006 103 14819 14824 10.1073/pnas.0604320103 17001007
111. Genome-scale RNAi profiling of cell division in human tissue culture cells. R Kittler L Pelletier AK Heninger M Slabicki M Theis L Miroslaw I Poser S Lawo H Grabner K Kozak,, et al. Nat Cell Biol 2007 9 1401 1412 10.1038/ncb1659 17994010
112. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. P Aza-Blanc CL Cooper K Wagner S Batalov QL Deveraux MP Cooke, Mol Cell 2003 12 627 637 10.1016/S1097-2765(03)00348-4 14527409
113. Genome-wide analysis of human kinases in clathrin-and caveolae/raft-mediated endocytosis. L Pelkmans E Fava H Grabner M Hannus B Habermann E Krausz M Zerial, Nature 2005 436 78 86 10.1038/nature03571 15889048
114. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. CS Collins J Hong L Sapinoso Y Zhou Z Liu K Micklash PG Schultz GM Hampton, Proc Natl Acad Sci USA 2006 103 3775 3780 10.1073/pnas.0600040103 16537454
115. Modular control of endothelial sheet migration. P Vitorino T Meyer, Genes Dev 2008 22 3268 3281 10.1101/gad.1725808 19056882
116. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. KJ Simpson LM Selfors J Bui A Reynolds D Leake A Khvorova JS Brugge, Nat Cell Biol 2008 10 1027 1038 10.1038/ncb1762 19160483
117. A functional genomic analysis of cell morphology using RNA interference. AA Kiger B Baum S Jones MR Jones A Coulson C Echeverri N Perrimon, J Biol 2003 2 27 10.1186/1475-4924-2-27 14527345
118. Identification of neural outgrowth genes using genome-wide RNAi. KJ Sepp P Hong SB Lizarraga JS Liu LA Mejia CA Walsh N Perrimon, PLoS Genet 2008 4 1000111 10.1371/journal.pgen.1000111 18604272
119. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. J Mullenders R Bernards, Oncogene 2009 28 4409 4420 10.1038/onc.2009.295 19767776
120. High-throughput approaches to dissecting MAPK signaling pathways. A Friedman N Perrimon, Methods 2006 40 262 271 10.1016/j.ymeth.2006.05.002 16844385
121. Identification of Hedgehog pathway components by RNAi in Drosophila cultured cells. L Lum S Yao B Mozer A Rovescalli D Von Kessler M Nirenberg PA Beachy, Science 2003 299 2039 2045 10.1126/science.1081403 12663920
122. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. K Berns EM Hijmans J Mullenders TR Brummelkamp A Velds M Heimerikx RM Kerkhoven M Madiredjo W Nijkamp B Weigelt,, et al. Nature 2004 428 431 437 10.1038/nature02371 15042092
123. A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling. A Friedman N Perrimon, Nature 2006 444 230 234 10.1038/nature05280 17086199
124. Identification of JAK/STAT signalling components by genome-wide RNA interference. P Muller D Kuttenkeuler V Gesellchen MP Zeidler M Boutros, Nature 2005 436 871 875 10.1038/nature03869 16094372
125. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. ME Davis JE Zuckerman CH Choi D Seligson A Tolcher CA Alabi Y Yen JD Heidel A Ribas, Nature 2010 464 1067 1070 10.1038/nature08956 20305636
126. Identification of selective inhibitors of cancer stem cells by high-throughput screening. PB Gupta TT Onder G Jiang K Tao C Kuperwasser RA Weinberg ES Lander, Cell 2009 138 645 659 10.1016/j.cell.2009.06.034 19682730
127. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. JC Yarrow G Totsukawa GT Charras TJ Mitchison, Chem Biol 2005 12 385 395 10.1016/j.chembiol.2005.01.015 15797222
128. Phenotypic screening of small molecule libraries by high throughput cell imaging. JC Yarrow Y Feng ZE Perlman T Kirchhausen TJ Mitchison, Comb Chem High Throughput Screen 2003 6 279 286 12769670
129. An efficient rapid system for profiling the cellular activities of molecular libraries. JS Melnick J Janes S Kim JY Chang DG Sipes D Gunderson L Jarnes JT Matzen ME Garcia TL Hood,, et al. Proc Natl Acad Sci USA 2006 103 3153 3158 10.1073/pnas.0511292103 16492761
130. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. TAT Fong LK Shawver L Sun C Tang H App TJ Powell YH Kim R Schreck X Wang W Risau,, et al. Cancer Research 1999 59 99 106 9892193
131. An in vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis and lymphangiogenesis. RE Kalin NE Banziger-Tobler M Detmar AW Brandli, Blood 2009 114 1110 1122 10.1182/blood-2009-03-211771 19478043
132. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. RJ Albuquerque T Hayashi WG Cho ME Kleinman S Dridi A Takeda JZ Baffi K Yamada H Kaneko MG Green,, et al. Nat Med 2009 15 1023 1030 10.1038/nm.2018 19668192
133. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. T Schomber A Zumsteg K Strittmatter I Crnic H Antoniadis A Littlewood-Evans J Wood G Christofori, Mol Cancer Ther 2009 8 55 63 10.1158/1535-7163.MCT-08-0679 19139113
134. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. T Makinen L Jussila T Veikkola T Karpanen MI Kettunen KJ Pulkkanen R Kauppinen DG Jackson H Kubo S Nishikawa,, et al. Nat Med 2001 7 199 205 10.1038/84651 11175851
135. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. D Hos F Bock T Dietrich J Onderka FE Kruse KH Thierauch C Cursiefen, Invest Ophthalmol Vis Sci 2008 49 1836 1842 10.1167/iovs.07-1314 18436817
136. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. CA Heckman T Holopainen M Wirzenius S Keskitalo M Jeltsch S Yla-Herttuala SR Wedge JM Jurgensmeier K Alitalo, Cancer Res 2008 68 4754 4762 10.1158/0008-5472.CAN-07- 5809 18559522
137. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. BL Falcon H Hashizume P Koumoutsakos J Chou JV Bready A Coxon JD Oliner DM McDonald, Am J Pathol 2009 175 2159 2170 10.2353/ajpath.2009.090391 19815705
138. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. R Cao MA Bjorndahl P Religa S Clasper S Garvin D Galter B Meister F Ikomi K Tritsaris S Dissing,, et al. Cancer Cell 2004 6 333 345 10.1016/j.ccr.2004.08.034 15488757
139. Anticancer strategies involving the vasculature. VL Heath R Bicknell, Nat Rev Clin Oncol 2009 6 395 404 10.1038/nrclinonc.2009.52 19424102